Adeno-Associated Viruses (AAVs) Analytical Workflows
Adeno-associated viruses (AAVs) have gathered significant attention, particularly for their role as vectors in gene therapy. AAVs exhibit promising qualities for this purpose due to their capability to infect both dividing and non-dividing cells with minimal immune response. Ensuring the reliable identification of AAV products is a prerequisite before their release.
Agilent offers comprehensive solutions designed to streamline AAV characterization and analysis, all the while overseeing crucial quality benchmarks.
The presentations will provide you with expertise on:
Complete the form for instance access to all the presentations.
Introduction to the Analysis of Adeno-Associated Virus Particles
Speaker: Dr. Andrew Coffey, Senior Application Chemist, Agilent Technologies, UK
Analytics of AAV based Gene Therapeutics
Speaker: Siva Sankar Bingi, MSc, Lead, Gene Therapy Department, CuraTeQ Biologics, India
AAV Capsid Protein Analysis using High Resolution LC/MS
Speaker: Richard Blankley, BioPharma Application Specialist, Agilent Technologies, UK
Multiple Peptide-Based Attributes of AAV with a Comprehensive LC/MS Method
Speaker: Wendi Hale Ph.D., Biocolumns Product Manager, Agilent Technologies, USA
DE89176145
Fill in the form below to gain access to the on-demand presentations
